1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
NextPlat's indirect subsidiary Progressive Care, LLC agreed on July 14, 2026 to acquire 100% of Scott's Pharmacy, LLC, a community pharmacy in Molino, Florida, for $1.5 million in cash, subject to an inventory adjustment. The filing says the pharmacy generated about $5.6 million in sales in 2025, and the deal is expected to expand NextPlat's PharmcoRx retail and contracted-services footprint in the panhandle region, though closing is not yet complete.
Purchase price is $1,500,000 in cash, with a $50,000 initial escrow deposit credited at closing and $50,000 held in escrow for indemnification for 18 months after closing.
Closing is targeted by September 30, 2026, with a one-time extension to October 31, 2026, available upon notice and an additional $50,000 deposit.
The Company has a 30-day due diligence period and must negotiate a lease for the premises; failure to do so allows termination without penalty.
Per the press release, the pharmacy had approximately $5.6 million in 2025 sales and retail margins of about 19%, and NextPlat's 2025 annual revenue was $54.3 million.
Stereotaxis completed its acquisition of Robocath, a French medical device company, on July 7, 2026, and filed supplemental risk factors. The filing says the deal will not be accretive and will increase Stereotaxis's operating losses in the near term, and that issuing shares for the earnout could dilute existing stockholders.
Stereotaxis issued 6,269,628 closing shares at the July 7, 2026 closing, including 225,000 shares paid to Robocath's financial advisor.
The Share Sale Agreement allows up to $25 million of earnout consideration, payable in cash, shares, or both, if regulatory and commercial milestones are met.
Stereotaxis registered 13,179,975 possible earnout shares, with a cap of 19.9% of shares outstanding as of July 7, 2026, including the closing shares.
Stereotaxis extended $1.1 million in operating loans to Robocath before closing; the loans were repaid at closing and reduced the upfront stock consideration.
SBA Communications agreed on July 14, 2026 to sell $3.5 billion of senior notes in a registered public offering through four underwriters. The company plans to use the net proceeds to repay in full its senior secured term loan and its outstanding revolving credit facility borrowings. The filing does not state the effect on earnings or leverage.
Notes: $1.35 billion of 4.875% due 2030, $1.35 billion of 5.150% due 2031, and $800 million of 5.450% due 2033
Underwriting agreement dated July 14, 2026, with Morgan Stanley, Barclays, Wells Fargo Securities and Goldman Sachs as representatives
Proceeds to repay the term loan maturing January 25, 2031 and revolver borrowings maturing January 25, 2029
Matson preliminarily estimated second-quarter 2026 operating income of $153.0 million to $160.0 million, net income of $124.8 million to $130.3 million, and diluted EPS of $4.12 to $4.30, all up year over year. The company attributed the increase mainly to higher contribution from its China service, and it also repurchased about 0.3 million shares for $67.8 million during the quarter.
Expected 2Q26 operating income of $153.0 to $160.0 million, versus $113.0 million in the prior-year quarter
Expected 2Q26 net income of $124.8 to $130.3 million and diluted EPS of $4.12 to $4.30, versus $94.7 million and $2.92
Repurchased about 0.3 million shares for $67.8 million in 2Q26; about 3.4 million shares remain under the program as of June 30, 2026
Second-quarter earnings call scheduled for August 3, 2026 at 4:30 p.m. ET
Home BancShares reported second quarter 2026 results that include its completed acquisition of Mountain Commerce Bancorp. Net income was $119.3 million and total revenue reached a company-record $295.1 million, up 10.6% from the first quarter. GAAP diluted EPS was $0.59, down from $0.60 in the prior quarter, while adjusted EPS was $0.64 after $12.7 million of merger-related expenses.
Net income of $119.3 million versus $118.2 million in Q1 2026 and $118.4 million in Q2 2025
Adjusted net income of $128.1 million, a company record, excluding merger expenses and certain other items
Total revenue (net) of $295.1 million, up 10.6% from $266.7 million; GAAP diluted EPS of $0.59 versus $0.60 in Q1 2026
Quarter-end total deposits of $19.11 billion, up from $17.74 billion at March 31, 2026, including the Mountain Commerce acquisition
The Hanover Insurance Group said CEO John C. Roche will retire as president, CEO and board member effective December 31, 2026. Chief Operating Officer Richard W. Lavey has been named CEO-elect and is expected to succeed Roche as CEO at that time, with a board seat from January 1, 2027. The filing reports no financial results, but it changes the company's top executive role.
John C. Roche, 62, retires as president, CEO and board member effective December 31, 2026, and stays as an advisor through January 8, 2027.
Richard W. Lavey, 59, has been Executive Vice President and Chief Operating Officer since March 2025 and is named CEO-elect.
The Board intends to elect Lavey to the Board effective January 1, 2027.
The company's earnings call is scheduled for July 29, 2026, and its investor day for September 17, 2026.
Samos Energy Acquisition Corporation closed its initial public offering of 23,000,000 units at $10.00 per unit on July 13, 2026, for gross proceeds of $230 million, including the full exercise of the underwriters' overallotment option. The company also sold 6,000,000 private placement warrants for $6 million and appointed three new directors, and it must complete a business combination within 24 months of the IPO closing or return public funds.
23,000,000 units sold at $10.00 each, for gross proceeds of $230 million, including 3,000,000 overallotment units (Exhibit 99.2)
Private sale of 6,000,000 warrants at $1.00 each on July 13, 2026, for gross proceeds of $6 million, to the Sponsor and Cantor
Trent Kososki, Joseph McMonigle and Khodor Mattar appointed directors on July 10, 2026; Mattar chairs the audit committee and McMonigle chairs the compensation committee
The 8-K says $200 million was deposited in trust, while Exhibit 99.2 says $230 million was placed in trust; the filing does not reconcile the two figures
Creative Media & Community Trust received a default notice on July 9, 2026 for the non-recourse mortgage on 1 Kaiser Plaza, which matured July 1, 2026. The company said it chose not to invest additional capital needed to refinance, and the lender has demanded immediate repayment and is collecting property rents, so shareholders face possible loss of this asset and uncertain resolution terms.
Notice of maturity default received July 9, 2026 on the 1 Kaiser Plaza mortgage, which matured July 1, 2026
Aggregate outstanding principal balance of the loan is $97.1 million as of the filing date
Lender has demanded immediate payment in full; property rents are now held for the lender and default interest may apply
Company remains current on monthly interest payments and is evaluating options, with no assurance on timing or outcome
Crescent Biopharma agreed on July 14, 2026 to sell 8,094,793 ordinary shares and pre-funded warrants for 525,897 more shares in a public offering, with gross proceeds expected to be about $125.0 million. The company says the net proceeds, together with existing cash, should fund projected operating expenses, working capital and capital expenditures into the second half of 2028, but the sale adds shares outstanding for existing holders.
Ordinary shares priced at $14.50 each; pre-funded warrants priced at $14.499 each, for 525,897 shares in total
Expected net proceeds of about $115.9 million, or about $133.5 million if the underwriters' 30-day option for 1,293,103 additional shares is exercised in full
Offering expected to close on July 16, 2026, subject to customary closing conditions
Company estimates cash will fund operations into the second half of 2028
Aldeyra received minutes from a June 10, 2026 Type A meeting with the FDA about potential resubmission of the New Drug Application for reproxalap, a treatment for dry eye disease. The company has asked the FDA for a clarification of the minutes and plans to request a Type D meeting to discuss resubmission, which is expected by the end of the third quarter of 2026.
Type A meeting with the FDA held June 10, 2026; minutes received July 14, 2026
Clarification of the minutes requested from the FDA on July 15, 2026
Type D meeting on NDA resubmission expected by end of third quarter 2026
Gladstone Land's board authorized repurchases of up to $20 million of its 6.00% Series B preferred stock and up to $35 million of its 6.00% Series C preferred stock, running through July 14, 2027. The company is not obligated to buy any particular amount, and the program can be suspended or discontinued at any time, so the effect on preferred holders and common shareholders will depend on how much is actually bought.
Series B authorization: up to $20,000,000 (Nasdaq: LANDO)
Series C authorization: up to $35,000,000 (Nasdaq: LANDP)
Program expires July 14, 2027; repurchases may be made through open market or privately negotiated transactions
Nomadar Corp. said it completed the acquisition of approximately 290,000 square meters of land in El Puerto de Santa María, Cádiz, Spain, for the planned JP Financial Arena. The closing follows binding agreements signed in April and May 2026 and gives the company effective control over the entire land asset. The filing does not disclose a purchase price, and it contains no financial results or guidance.
Land totals about 290,000 square meters, including about 130,000 square meters from an April 2026 binding offer and about 161,000 additional square meters from a May 2026 binding agreement.
Closing was announced July 15, 2026, and Nomadar says it now has effective control over the entire strategic land asset.
The filing does not state the purchase price or how the acquisition will be funded.
J.B. Hunt Transport Services reported second quarter 2026 net earnings of $181.0 million, or $1.91 per diluted share, versus $128.6 million, or $1.31 per share, a year earlier. Total operating revenue rose 19% to $3.50 billion, and operating income rose 32% to $259.5 million, though fuel surcharge revenue accounted for part of the revenue gain. For shareholders, the quarter shows higher earnings per share, and the company bought back about 392,000 shares for about $98 million in the quarter.
Net earnings $181.0 million vs. $128.6 million; diluted EPS $1.91 vs. $1.31 (up 45%)
Revenue $3.50 billion, up 19%; excluding fuel surcharge revenue, up 11%
Intermodal operating income $150.9 million, up 58%; Truckload posted a $1.3 million operating loss
Debt about $1.15 billion at June 30, 2026, vs. $1.72 billion a year earlier; 2026 tax rate expected at 24.0% to 24.5%
RxSight's board appointed Aziz Mottiwala as President and Chief Executive Officer on July 13, 2026, effective July 20, 2026, replacing Ron Kurtz, M.D., who has led the company since 2016. Kurtz moves to Chief Medical Officer and resigns from the board, and Mottiwala joins the board in his place. The company said it is not updating its previously communicated financial guidance.
Mottiwala, 48, was Chief Commercial Officer of Tarsus Pharmaceuticals from August 2020 to July 2026.
Mottiwala's pay includes a $750,000 base salary, a 2026 cash bonus of $337,500, and equity awards with a grant-date value of $14,000,000.
Kurtz keeps a $740,000 base salary and can earn retention bonuses of $370,000 on each of four dates from January 1, 2027 through July 1, 2028, if he remains employed.
The company is not updating its previously communicated financial guidance in connection with the announcement.
Prudential Financial disclosed preliminary second-quarter 2026 results before its August 4, 2026 earnings release, while its financial closing is not complete and actual results could differ materially. The company also reported that its annual actuarial assumption review will lead to one-time segment adjustments to adjusted operating income (AOI) in the quarter, with no material ongoing AOI impact expected.
PGIM assets under management were $1.49 trillion as of June 30, 2026, and PGIM other related revenues, net of related expenses, were approximately $60 million on an AOI basis for the quarter.
General Account alternative investment income for the quarter is estimated to be $20 million to $40 million below near-term expectations.
One-time AOI impacts: Retirement $(90) million; International Businesses $80 million; Group Insurance $30 million; Individual Life $30 million; U.S. Legacy Products $15 million, which sum to a net $65 million.
The earnings release and quarterly financial supplement are scheduled for August 4, 2026.
On July 12, 2026, First Hawaiian, Inc. signed a merger agreement with TriCo Bancshares, under which TriCo will merge into a First Hawaiian subsidiary and then into First Hawaiian, followed by a bank merger of Tri Counties Bank into First Hawaiian Bank. TriCo shareholders will receive 2.095 First Hawaiian shares for each TriCo share, so the deal would dilute existing First Hawaiian shareholders and depends on shareholder, regulatory and registration approvals.
Exchange ratio: each TriCo common share converts into 2.095 First Hawaiian common shares, with cash paid in lieu of fractional shares
Termination fee of $80 million payable by either party in certain circumstances
Four TriCo directors will join the First Hawaiian board at the effective time
Closing requires stockholder and shareholder approvals, Federal Reserve, FDIC and state regulatory approvals, and effectiveness of a Form S-4 registration statement
Celsius Holdings amended its credit agreement on July 15, 2026, cutting the interest rate on its term loan by 0.25%, with a possible further 0.25% cut tied to achieving certain credit ratings. The company used a new $694.75 million term loan to fully repay the $700 million existing term loan, with no prepayment penalties, which lowers borrowing costs for shareholders.
Second Amendment reduces the Term Loan Facility interest rate by 0.25%, with a potential additional 0.25% cut if certain public corporate or corporate family ratings are achieved on an ongoing basis
New term loan of $694.75 million repaid the entire $700 million Existing Term Loan on July 15, 2026
No prepayment penalties were incurred; Revolving Facility interest rate is unchanged
Marwynn Holdings, Inc. disclosed that Nasdaq notified it on July 10, 2026, that it had regained compliance with the $1.00 minimum bid price requirement for continued listing. The company had received a deficiency notice on January 29, 2026, and had until July 28, 2026 to regain compliance. The filing shows the stock closed at or above $1.00 for 10 consecutive business days, which removes the risk of delisting on this issue.
Nasdaq deficiency notice received January 29, 2026, for bid price below $1.00 for 30 consecutive business days
Nasdaq letter dated July 10, 2026, confirmed compliance with Listing Rule 5550(a)(2)
Closing bid price at or above $1.00 for 10 consecutive business days, June 25 to July 9, 2026
Martin Marietta entered a $1.5 billion three-year senior unsecured term loan on July 15, 2026, and amended its $800 million revolving credit facility on July 10, 2026. Both are tied to its previously announced acquisition of Lhoist North America, with the term loan's proceeds usable to pay part of the cash consideration. The filing sets a maximum leverage ratio that steps down after the deal closes, which shows the debt load the company will carry.
Term Facility: $1,500,000,000 three-year senior unsecured term loan with JPMorgan Chase Bank, N.A. as administrative agent, available subject to the Lhoist North America acquisition closing
Revolving facility amendment dated July 10, 2026 sets maximum leverage ratio of 4.75:1.00 for the first three fiscal quarters after closing, 4.25:1.00 for the next three, and 3.75:1.00 thereafter
Commitment fee on undrawn term loan commitments begins October 25, 2026
Prestige Brands, a wholly owned subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due July 15, 2034, under an indenture dated July 15, 2026. The notes are unsecured and guaranteed by the parent company, adding $400 million of long-term debt that shareholders will carry alongside existing obligations.
Principal amount: $400.0 million of 6.250% senior notes due July 15, 2034
Interest payable January 15 and July 15 each year, starting January 15, 2027
Parent company and certain domestic subsidiaries guarantee the notes on an unsecured senior basis
Change of Control triggers an offer to repurchase at 101% of principal; notes may be redeemed from July 15, 2029
United Airlines Holdings reported second-quarter 2026 results, with total operating revenue of $17.7 billion, up 16.0% from a year earlier, and diluted earnings per share of $2.46 (adjusted $1.99). It raised its full-year 2026 adjusted diluted EPS guidance to $9.00-$11.00, but expects nearly $6 billion in added fuel expense for the year versus its January expectation, which is the main cost pressure for shareholders.
Q2 2026 total operating revenue $17.7 billion, up 16.0%; net income $805 million; pre-tax earnings $1.0 billion
Full-year 2026 adjusted diluted EPS guidance raised to $9.00-$11.00
Q2 aircraft fuel expense rose $2.3 billion, or 84%; company expects to recover 80%-90% of the increase in Q3 and 100% by Q4
Ending available liquidity of $19.6 billion; total debt and lease obligations of $26.5 billion at quarter end
Tennessee Valley Authority entered into a Third Amended and Restated $1 billion July Maturity Credit Agreement on July 10, 2026, replacing its March 2022 facility. The agreement allows TVA to borrow or obtain letters of credit of up to $1 billion and expires on July 10, 2031, unless extended, so it adds a revolving source of liquidity with a long maturity for shareholders to note.
Facility size: up to $1 billion in loans or letters of credit
Agreement dated July 10, 2026; expires July 10, 2031 unless extended
Administrative Agent: Toronto Dominion (Texas) LLC; Lead Arranger and Bookrunner: TD Securities (USA) LLC
Interest rate and unused facility fee vary with the rating of TVA's senior unsecured long-term non-credit enhanced debt
Union Bankshares reported second-quarter 2026 net income of $2.9 million, or $0.61 per share, up from $2.4 million, or $0.53 per share, a year earlier. Six-month net income was $5.9 million, or $1.26 per share, compared with $4.9 million, or $1.08 per share, in the same period of 2025. The board also declared a $0.36 quarterly dividend, and the press release describes a leadership transition in which David S. Silverman is moving from chief executive to chair.
Q2 2026 net income $2.9 million, or $0.61 per share, versus $2.4 million, or $0.53 per share, in Q2 2025
Six months ended June 30, 2026 net income $5.9 million, or $1.26 per share, versus $4.9 million, or $1.08 per share
Quarterly cash dividend of $0.36 per share, payable August 6, 2026 to holders of record as of July 27, 2026
Jeffrey F. Weidley is president and CEO; David S. Silverman is transitioning from CEO to Chair of the Board
American Express reported June 2026 credit statistics for its U.S. Consumer and U.S. Small Business Card balances held for investment. Write-off and delinquency rates improved in June, but the company said a sale of previously written-off balances to a third party reduced the June write-off rates.
U.S. Consumer net write-off rate (principal only) was 1.4% in June 2026, versus 2.0% in May and 2.1% in April.
U.S. Small Business net write-off rate was 2.3% in June 2026, versus 2.6% in May and 2.4% in April.
The June sale reduced the net write-off rates by about 0.3% for U.S. Consumer and 0.1% for U.S. Small Business.
Total held-for-investment Card balances were $159.7 billion at June 30, 2026, down from $160.5 billion at May 31, 2026.
Winmark reported second-quarter net income of $10.4 million, or $2.81 per diluted share, for the quarter ended June 27, 2026, compared with $10.6 million, or $2.89 per diluted share, a year earlier. Total revenue rose to $22.0 million from $20.4 million, while selling, general and administrative expenses increased to $7.5 million from $6.6 million. The Board also approved a quarterly dividend of $1.02 per share, payable September 1, 2026.
Q2 total revenue was $21,966,000 versus $20,416,800 a year earlier; royalties were $20,117,000 versus $18,662,100.
Q2 diluted EPS was $2.81 versus $2.89; six-month diluted EPS was $5.31 versus $5.60.
Prior-year six-month results included $2.2 million of leasing income from the settlement of customer litigation.
Quarterly dividend of $1.02 per share: record date August 12, 2026; payment date September 1, 2026.
Progressive reported June 2026 results in a news release filed with the SEC. June net income fell to $779 million from $1,124 million a year earlier, and earnings per share fell to $1.34 from $1.91, while net premiums written rose 3% to $6,772 million. The combined ratio rose to 90.0 from 86.6, so underwriting profitability weakened in the month even as premium volume grew.
June net income was $779 million, down 31% from $1,124 million a year earlier.
June earnings per share were $1.34, compared with $1.91 a year earlier.
June net premiums written were $6,772 million, up 3%; the combined ratio was 90.0 versus 86.6.
Year-to-date net income was $6,129 million, up from $5,742 million for the same period in 2025.
Sprout Social said its board approved a workforce reduction of about 20%, or about 260 employees, on July 8, 2026, and began notifying affected employees on July 15. The company estimates pre-tax restructuring charges of $18.0 million to $20.0 million, mostly severance, with substantially all recognized in the third quarter of 2026. It also said preliminary results for the quarter ended June 30, 2026 are expected at the high end of its outlook ranges for revenue, non-GAAP operating income and non-GAAP net income per share, with full results due August 6, 2026.
Workforce reduction of about 20%, or about 260 employees, approved July 8, 2026; notifications began July 15, 2026
Estimated pre-tax restructuring charges of $18.0 million to $20.0 million, mainly cash severance and benefits, with substantially all recognized in Q3 2026
Preliminary Q2 2026 results expected at the high end of outlook ranges for revenue, non-GAAP operating income and non-GAAP EPS; full results due August 6, 2026 after market close
Veradermics said topline results from its open-label Phase 2 Study 207 showed increases in hair count and patient-reported improvement in women with mild-to-moderate pattern hair loss after six months of oral VDPHL01 treatment. The company said the results support its registration-directed Phase 2/3 Study 306 in women, with topline data expected in the first half of 2027. The filing contains no financial results, and the study was open-label.
Study 207 enrolled 28 adult female participants; women on VDPHL01 4.5 mg once daily or twice daily showed mean non-vellus hair count increases of 22.7 and 23.3 hairs/cm² at Month 6.
88.9% (once daily) and 90.0% (twice daily) of women rated improved or much improved on the AAIRS at Month 6.
No treatment-related serious adverse events were reported; the most common adverse events were hypertrichosis and peripheral edema.
Topline results from Phase 2/3 Study 306 in women are anticipated in the first half of 2027.
Cintas reported fiscal 2026 fourth-quarter results for the quarter ended May 31, 2026, with revenue up 8.9%, diluted EPS up 15.6% to $1.26, and adjusted diluted EPS up 18.3% to $1.29. For fiscal 2027 it guided to revenue of $12.10 billion to $12.25 billion and adjusted diluted EPS of $5.36 to $5.50, excluding the proposed UniFirst acquisition.
Q4 fiscal 2026 revenue was $2.91 billion, up 8.9%; organic revenue growth was 8.4%
Q4 gross margin was 51.0% of revenue, equal to the all-time high; diluted EPS was $1.26 and adjusted diluted EPS was $1.29
Fiscal 2027 guidance: revenue of $12.10 billion to $12.25 billion and adjusted diluted EPS of $5.36 to $5.50, excluding UniFirst deal impacts
UniFirst acquisition: shareholders approved on June 11, 2026, and the FTC issued a second request; Cintas still expects closing in the second half of calendar 2026
Morgan Stanley reported second-quarter 2026 net revenues of $21.3 billion, up from $16.8 billion a year earlier, and diluted EPS of $3.46 versus $2.13. The board also reauthorized a share repurchase program of up to $20 billion and raised the quarterly dividend by 15 cents to $1.15 per share, which matters to shareholders because it signals both higher earnings and expanded capital return.
Net income applicable to Morgan Stanley was $5.6 billion, or $3.46 per diluted share, versus $3.5 billion, or $2.13, a year ago.
The board reauthorized a multi-year common stock repurchase program of up to $20 billion, starting in the third quarter of 2026, with no set expiration date.
The quarterly dividend was raised to $1.15 per share, payable August 14, 2026, to shareholders of record on July 31, 2026.
Johnson & Johnson reported second-quarter 2026 reported sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, up 4.7%, while GAAP diluted EPS was $2.27, down 0.9%. The company raised its 2026 adjusted EPS guidance by $0.13 to a midpoint of $11.68, which signals stronger expected profit for shareholders this year.
Q2 2026 reported sales were $25.3 billion, up 6.6% from $23.7 billion a year earlier.
GAAP diluted EPS was $2.27 versus $2.29 in Q2 2025; net earnings were $5.5 billion, down 0.1%.
Adjusted diluted EPS was $2.90 versus $2.77, up 4.7%.
2026 adjusted EPS guidance midpoint rose to $11.68, up $0.13, with estimated reported sales midpoint of $101.1 billion.
Conagra reported a fourth-quarter fiscal 2026 net loss of $1.6 billion, or $3.37 per diluted share, driven by $2.0 billion of non-cash goodwill and brand impairment charges, while adjusted EPS was $0.47. The board approved a quarterly dividend of $0.175 per share, an annualized rate of $0.70, and the company gave fiscal 2027 adjusted EPS guidance of $1.40 to $1.50, with new CEO John Brase citing margin restoration as a priority.
Q4 reported net sales rose 3.6% to $2.9 billion, but organic net sales were approximately flat
Full-year fiscal 2026 diluted loss was $4.00 per share; adjusted EPS was $1.72
Fiscal 2027 guidance: organic net sales down 3% to 1%, adjusted operating margin 10.0% to 10.5%, adjusted EPS $1.40 to $1.50
Quarterly dividend of $0.175 per share, payable September 2, 2026, to holders of record July 30, 2026
Axsome Therapeutics said the FDA accepted its New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 is not approved by the FDA, and the filing contains no financial results.
FDA accepted the New Drug Application for AXS-12 (reboxetine) for cataplexy in narcolepsy for filing
PDUFA target action date set for May 1, 2027
FDA does not currently plan to hold an advisory committee meeting
AXS-12 has FDA Orphan Drug Designation for the treatment of narcolepsy
Pediatrix Medical Group said in a July 15, 2026 update on its second quarter that its payor mix stayed stable and in line with recent trends and internal expectations, and it has not seen material changes in other net revenue trends. The company reaffirmed its full year 2026 Adjusted EBITDA outlook of $280 million to $300 million, and it did not report second quarter financial results in this filing. Full results are due in a release on August 4, 2026.
Full year 2026 Adjusted EBITDA outlook reaffirmed at $280 million to $300 million
Second quarter payor mix stable and unchanged relative to recent historical trends and internal expectations
Company says it has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector
Investor conference call and detailed results release scheduled for August 4, 2026, at 9:00 a.m. ET
PNC reported second quarter 2026 net income of $2.1 billion, or $4.81 per diluted share, and $4.85 per share as adjusted for FirstBank integration costs and other significant items. Total revenue rose to $6.9 billion, up 12% from the first quarter and 21% from a year earlier, and the board raised the quarterly dividend 18% to $2.00 per share, which matters to shareholders because it increases the cash return on each share.
Net income of $2.1 billion and diluted EPS of $4.81, compared with $4.13 in the first quarter of 2026 and $3.85 in the second quarter of 2025
Total revenue of $6.9 billion, up $710 million from the first quarter and $1.2 billion from the second quarter of 2025
Quarterly dividend raised to $2.00 per share from $1.70, payable August 5, 2026 to holders of record on July 20, 2026
Visa exchange gain of $448 million was largely offset by a $140 million PNC Foundation contribution and a $139 million securities loss
BlackRock reported second quarter 2026 results, with diluted EPS of $12.19, up 20% from $10.19 a year earlier, and $13.91 as adjusted, up 15%. Revenue rose 31% to $7.08 billion and operating income rose 42% to $2.46 billion, and the company raised its planned quarterly share repurchases to $550 million, which matters to shareholders because it signals a larger return of capital.
Q2 2026 revenue was $7,084 million, up from $5,423 million; operating income was $2,461 million, up from $1,731 million.
Q2 2026 long-term net inflows were $199 billion; total net inflows were $192 billion, and first-half net inflows were $321 billion.
Company repurchased $450 million of shares in the quarter and increased planned quarterly repurchases to $550 million.
Assets under management reached $15.3 trillion at June 30, 2026.
First Horizon reported second quarter 2026 net income available to common shareholders of $260 million, or $0.54 per diluted share, up from $233 million and $0.45 a year earlier. Results improved from the first quarter, when the company reported $257 million and $0.53 per share, and the company's return on common equity was 12.3%.
Net income available to common shareholders was $260 million, up 12% from $233 million in second quarter 2025.
Diluted EPS was $0.54, compared with $0.53 in first quarter 2026 and $0.45 in second quarter 2025.
Noninterest expense rose to $531 million, up $26 million from the prior quarter; the net interest margin was 3.49%, down 3 basis points.
Share repurchases totaled $100 million at an average price of $24.52 per share, and the CET1 ratio was 10.5%.
BNY reported second-quarter 2026 results on July 15, 2026, with total revenue of $5.7 billion, up 13% from a year earlier, and diluted earnings per share of $2.45, up 27% from $1.93. Net income applicable to common shareholders rose 22% to $1.7 billion, and the company returned $1.5 billion to common shareholders in the quarter.
Total revenue of $5,698 million, up 13% year over year and 5% from the first quarter of 2026
Diluted EPS of $2.45, compared with $1.93 a year earlier and $2.24 in the first quarter of 2026
Noninterest expense of $3.4 billion, up 7% year over year; pre-tax operating margin of 39.8%
Returned $1.5 billion to common shareholders: $1.1 billion in share repurchases and $371 million in dividends; CET1 ratio of 11.0%
SemiLEDs disclosed that Nasdaq had notified it on January 30, 2026 that its stockholders' equity fell below the $2.5 million minimum, and that Nasdaq accepted its compliance plan with an extension of up to 180 calendar days. The company now believes it has regained compliance, based on stockholders' equity of $3.1 million as of May 31, 2026, but Nasdaq will keep monitoring and could start delisting if the next periodic report does not show compliance.
Nasdaq notice dated January 30, 2026 cited stockholders' equity below the $2.5 million minimum under Listing Rule 5550(b)(1)
Nasdaq accepted the company's plan and granted an extension of up to 180 calendar days from January 30, 2026
Total stockholders' equity was $3.1 million as of May 31, 2026, per the Form 10-Q
Company believes it has regained compliance; Nasdaq will monitor compliance in the next periodic report
M&T Bank Corporation reported second quarter 2026 net income of $818 million, up 14% from $716 million a year earlier, and diluted earnings of $5.32 per share, up from $4.24. The company said the results reflect strong contributions from its commercial, retail, institutional services and wealth management businesses, and it repurchased $465 million of its common stock during the quarter.
Net income of $818 million vs. $716 million in Q2 2025 and $664 million in Q1 2026
Diluted earnings per share of $5.32, vs. $4.24 in Q2 2025 and $4.13 in Q1 2026
Net operating income of $823 million; net interest margin steady at 3.70%
Provision for credit losses fell to $120 million from $140 million in Q1 2026; nonaccrual loans were $1.2 billion at June 30, 2026
Elevance Health reported second-quarter 2026 operating revenue of $49.8 billion, up 0.8% from a year earlier, while diluted earnings per share fell 13.1% to $6.71 from $7.72. The company raised its full-year 2026 diluted EPS guidance to at least $20.10 and its adjusted EPS guidance to at least $27.00, and said it is accelerating targeted investments. For shareholders, the higher outlook comes alongside lower quarterly profit and a higher benefit expense ratio.
Operating revenue was $49.8 billion in the second quarter of 2026, up from $49.4 billion a year earlier.
Diluted EPS was $6.71 versus $7.72 a year earlier; adjusted diluted EPS was $7.45 versus $8.84.
Full-year 2026 diluted EPS guidance was raised to at least $20.10 and adjusted diluted EPS guidance to at least $27.00.
Full-year 2026 operating cash flow guidance was raised to at least $6.0 billion; a $1.72 quarterly dividend is payable September 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.